Epigenome Editing: State of the Art, Concepts, and Perspectives

Trends in Genetics

Volumn 32, Issue 2, 2016, Pages 101-113

  Kungulovski, Goran ^a   Jeltsch, Albert ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Cell reprogramming; Chromatin modification; DNA recognition; Gene regulation; Molecular epigenetics; Synthetic biology

Indexed keywords

ACYLTRANSFERASE; DEUBIQUITINASE; DIOXYGENASE; DNA; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; METHYLCYTOSINE DIOXYGENASE; METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN LYSINE ACETYLTRANSFERASE; PROTEIN LYSINE DEACETYLASE I; PROTEIN LYSINE DEACETYLASE IIA; PROTEIN LYSINE DEACETYLASE IIB; PROTEIN LYSINE DEACETYLASE IV; PROTEIN LYSINE DEMETHYLASE; PROTEIN LYSINE METHYLTRANSFERASE; SIRTUIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; UNCLASSIFIED ENZYME; CHROMATIN;

BASIC RESEARCH; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CLINICAL RESEARCH; EPIGENETICS; EPIGENOME EDITING; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; GENETIC ENGINEERING AND GENE TECHNOLOGY; GENETIC STABILITY; GENOME; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; SYNTHETIC BIOLOGY; CHROMATIN; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PROCEDURES; PROTEIN DOMAIN;

CELLULAR REPROGRAMMING; CHROMATIN; DNA; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION; HUMANS; PROTEIN DOMAINS; SYNTHETIC BIOLOGY;

EID: 84958600233     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2015.12.001     Document Type: Review

References (93)

1. Allis C.D., et al. Epigenetics 2015, Cold Spring Harbor Laboratory Press.
2. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13:343-357.
3. Jeltsch A., Jurkowska R.Z. New concepts in DNA methylation. Trends Biochem. Sci. 2014, 39:310-318.
4. The ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74.
5. Rivera C.M., Ren B. Mapping human epigenomes. Cell 2013, 155:39-55.
6. Kundaje A., et al. Integrative analysis of 111 reference human epigenomes. Nature 2015, 518:317-330.
7. Wu S.C., Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 2010, 11:607-620.
8. Seeman N.C., et al. Sequence-specific recognition of double helical nucleic acids by proteins. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:804-808.
9. Jeltsch A., et al. Engineering novel restriction endonucleases: principles and applications. Trends Biotechnol. 1996, 14:235-238.
10. Gaj T., et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405.
11. Wolfe S.A., et al. DNA recognition by Cys2His2 zinc finger proteins. Annu. Rev. Biophys. Biomol. Struct. 2000, 29:183-212.
12. Pabo C.O., et al. Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 2001, 70:313-340.
13. Jamieson A.C., et al. Drug discovery with engineered zinc-finger proteins. Nat. Rev. Drug Discov. 2003, 2:361-368.
14. Boch J., et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326:1509-1512.
15. Bogdanove A.J., Voytas D.F. TAL effectors: customizable proteins for DNA targeting. Science 2011, 333:1843-1846.
16. Jinek M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337:816-821.
17. Qi L.S., et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152:1173-1183.
18. Mussolino C., et al. TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res. 2014, 42:6762-6773.
19. Mussolino C., Cathomen T. On target? Tracing zinc-finger-nuclease specificity. Nat. Methods 2011, 8:725-726.
20. Grimmer M.R., et al. Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res. 2014, 42:10856-10868.
21. Tsai S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 2015, 33:187-197.
22. Polstein L.R., et al. Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Res. 2015, 25:1158-1169.
23. O'Geen H., et al. How specific is CRISPR/Cas9 really?. Curr. Opin. Chem. Biol. 2015, 29:72-78.
24. Doudna J.A., Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346:1258096.
25. Mussolino C., et al. Proven and novel strategies for efficient editing of the human genome. Curr. Opin. Pharmacol. 2015, 24:105-112.
26. Jeltsch A., et al. Application of DNA methyltransferases in targeted DNA methylation. Appl. Microbiol. Biotechnol. 2007, 75:1233-1240.
27. de Groote M.L., et al. Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res. 2012, 40:10596-10613.
28. Xu G.L., Bestor T.H. Cytosine methylation targetted to pre-determined sequences. Nat. Genet. 1997, 17:376-378.
29. Snowden A.W., et al. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr. Biol. 2002, 12:2159-2166.
30. Keung A.J., et al. Chromatin regulation at the frontier of synthetic biology. Nat. Rev. Genet. 2015, 16:159-171.
31. Jurkowski T.P., et al. Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity. Clin. Epigenetics 2015, 7:18.
32. Li F., et al. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res. 2007, 35:100-112.
33. Rivenbark A.G., et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012, 7:350-360.
34. Siddique A.N., et al. Targeted methylation and gene silencing of VEGF-in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J. Mol. Biol. 2013, 425:479-491.
35. Falahi F., et al. Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol. Cancer Res. 2013, 11:1029-1039.
36. Gregory D.J., et al. Specific transcriptional enhancement of inducible nitric oxide synthase by targeted promoter demethylation. Epigenetics 2013, 8:1205-1212.
37. Chen H., et al. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-promoter. Nucleic Acids Res. 2014, 42:1563-1574.
38. Nunna S., et al. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS ONE 2014, 9:e87703.
39. Heller E.A., et al. Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. Nat. Neurosci. 2014, 17:1720-1727.
40. Keung A.J., et al. Using targeted chromatin regulators to engineer combinatorial and spatial transcriptional regulation. Cell 2014, 158:110-120.
41. Kungulovski G., et al. Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained. Epigenetics Chromatin 2015, 8:12.
42. Stolzenburg S., et al. Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene 2015, 34:5427-5435.
43. Hilton I.B., et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 2015, 33:510-517.
44. Mendenhall E.M., et al. Locus-specific editing of histone modifications at endogenous enhancers. Nat. Biotechnol. 2013, 31:1133-1136.
45. Maeder M.L., et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 2013, 31:1137-1142.
46. Konermann S., et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013, 500:472-476.
47. Bernstein D.L., et al. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. J. Clin. Invest. 2015, 125:1998-2006.
48. Cho H.S., et al. Direct regulation of E-cadherin by targeted histone methylation of TALE-SET fusion protein in cancer cells. Oncotarget 2015, 6:23837-23844.
49. Kearns N.A., et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods 2015, 12:401-403.
50. Blackledge N.P., et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell 2014, 157:1445-1459.
51. Ragunathan K., et al. Epigenetic inheritance uncoupled from sequence-specific recruitment. Science 2015, 348:1258699.
52. Audergon P.N., et al. Restricted epigenetic inheritance of H3K9 methylation. Science 2015, 348:132-135.
53. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012, 10:678-684.
54. Vasileva E.A., et al. Genome-editing tools for stem cell biology. Cell Death Dis. 2015, 6:e1831.
55. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
56. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 2008, 8:57-64.
57. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:243-263.
58. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
59. Bashtrykov P., Jeltsch A. DNMT1-associated DNA methylation changes in cancer. Cell Cycle 2015, 14:5.
60. Guo X., et al. Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature 2015, 517:640-644.
61. Southall S.M., et al. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol. Cell 2009, 33:181-191.
62. Al-Sady B., et al. Division of labor between the chromodomains of HP1 and Suv39 methylase enables coordination of heterochromatin spread. Mol. Cell 2013, 51:80-91.
63. Qiao Q., et al. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J. Biol. Chem. 2011, 286:8361-8368.
64. Nayerossadat N., et al. Viral and nonviral delivery systems for gene delivery. Adv. Biomed. Res. 2012, 1:27.
65. Yohan D., Chithrani B.D. Applications of nanoparticles in nanomedicine. J. Biomed. Nanotechnol. 2014, 10:2371-2392.
66. Jurkowska R.Z., et al. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12:206-222.
67. Kohli R.M., Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013, 502:472-479.
68. Cheng X., et al. Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 2005, 34:267-294.
69. Mosammaparast N., Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu. Rev. Biochem. 2010, 79:155-179.
70. Fuhrmann J., et al. Chemical biology of protein arginine modifications in epigenetic regulation. Chem. Rev. 2015, 115:5413-5461.
71. Berndsen C.E., Denu J.M. Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr. Opin. Struct. Biol. 2008, 18:682-689.
72. Lombardi P.M., et al. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol. 2011, 21:735-743.
73. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73:417-435.
74. Rossetto D., et al. Histone phosphorylation: a chromatin modification involved in diverse nuclear events. Epigenetics 2012, 7:1098-1108.
75. Cao J., Yan Q. Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front. Oncol. 2012, 2:26.
76. Atanassov B.S., et al. The role of deubiquitinating enzymes in chromatin regulation. FEBS Lett. 2011, 585:2016-2023.
77. Wang S., Wang Y. Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim. Biophys. Acta 2013, 1829:1126-1135.
78. Hottiger M.O. Nuclear ADP-ribosylation and its role in chromatin plasticity, cell differentiation, and epigenetics. Annu. Rev. Biochem. 2015, 84:227-263.
79. Archin N.M., Margolis D.M. Emerging strategies to deplete the HIV reservoir. Curr. Opin. Infect. Dis. 2014, 27:29-35.
80. Wang P., et al. Specific reactivation of latent HIV-with designer zinc-finger transcription factors targeting the HIV-5'-LTR promoter. Gene Ther. 2014, 21:490-495.
81. Aguzzi A., O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9:237-248.
82. Eisele Y.S., et al. Targeting protein aggregation for the treatment of degenerative diseases. Nat. Rev. Drug Discov. 2015, 14:759-780.
83. Horsthemke B., Buiting K. Genomic imprinting and imprinting defects in humans. Adv. Genet. 2008, 61:225-246.
84. Adalsteinsson B.T., Ferguson-Smith A.C. Epigenetic control of the genome - lessons from genomic imprinting. Genes 2014, 5:635-655.
85. Bashtrykov P., et al. Correction of aberrant imprinting by allele specific epigenome editing. Clin. Pharmacol. Ther. 2015, Published online November 4, 2015. 10.1002/cpt.295.
86. Yoshimi K., et al. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. Nat. Commun. 2014, 5:4240.
87. Cameron N.M., et al. Epigenetic programming of phenotypic variations in reproductive strategies in the rat through maternal care. J. Neuroendocrinol. 2008, 20:795-801.
88. Zovkic I.B., et al. Epigenetic regulation of memory formation and maintenance. Learn. Mem. 2013, 20:61-74.
89. Klengel T., Binder E.B. Allele-specific epigenetic modification: a molecular mechanism for gene-environment interactions in stress-related psychiatric disorders?. Epigenomics 2013, 5:109-112.
90. Nugent B.M., et al. Brain feminization requires active repression of masculinization via DNA methylation. Nat. Neurosci. 2015, 18:690-697.
91. Jakovcevski M., Akbarian S. Epigenetic mechanisms in neurological disease. Nat. Med. 2012, 18:1194-1204.
92. Swiech L., et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 2015, 33:102-106.
93. Kanherkar R.R., et al. Cellular reprogramming for understanding and treating human disease. Front. Cell Dev. Biol. 2014, 2:67.